Black Diamond Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Black Diamond Therapeutics

10/08/2022 14:31

* Black Diamond Therapeutics Inc  BDTX.OQ  reported a
quarterly
adjusted loss of 63 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 68 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Black Diamond Therapeutics Inc's reported EPS for the
quarter
was a loss of 63 cents​.
    * The mean earnings estimate of analysts had risen by
about 11.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Black Diamond Therapeutics Inc shares had risen by 54.1%
this
quarter and lost 28.9% so far this year.
    * The company reported a quarterly loss of $22.93 million.
    * Wall Street's median 12-month price target for Black
Diamond
Therapeutics Inc is $4.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 10
at 01:31 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.68          -0.63          Beat
 Mar. 31 2022      -0.75          -0.70          Beat
 Dec. 31 2021      -1.01          -0.71          Beat
 Sep. 30 2021      -0.98          -0.97          Beat